Biology:V-01
From HandWiki
Revision as of 02:54, 22 October 2021 by imported>Smart bot editor (update)
Short description: Vaccine candidate against COVID-19
| Vaccine description | |
|---|---|
| Target disease | SARS-CoV-2 |
| Type | Protein subunit |
| Clinical data | |
| Routes of administration | Intramuscular |
V-01 is a COVID-19 vaccine candidate developed by a subsidiary of Livzon Pharmaceutical Group Inc.[1][2][3]
References
- ↑ "China approves clinical trials for Livzon Pharma unit's COVID-19 vaccine". Reuters. 23 March 2021. https://www.reuters.com/article/us-health-coronavirus-vaccine-livzon-idUSKBN2BF20A.
- ↑ "评价重组新型冠状病毒融合蛋白疫苗在健康人群免疫原性和安全性随机、双盲、安慰剂对照的Ⅱ期临床试验". Chinese Clinical Trial Registry. http://www.chictr.org.cn/showproj.aspx?proj=124702.
- ↑ "评价重组新型冠状病毒融合蛋白疫苗在健康人群安全性和免疫原性随机、双盲、安慰剂对照的Ⅰ期临床试验". Chinese Clinical Trial Registry. http://www.chictr.org.cn/showproj.aspx?proj=124140.
 |
